Trial Profile
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs CMV-pp65-vaccine-PepVax (Primary) ; Letermovir
- Indications Cytomegalovirus infections
- Focus Pharmacodynamics
- 14 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 15 May 2023 Planned primary completion date changed from 30 Apr 2023 to 31 Dec 2023.
- 20 Mar 2023 Planned End Date changed from 31 Mar 2023 to 31 Dec 2023.